WO1999036082A3 - The use of increased neurofilament protein levels as protection and therapy against neurodegeneration with oxidative stress involvement - Google Patents

The use of increased neurofilament protein levels as protection and therapy against neurodegeneration with oxidative stress involvement Download PDF

Info

Publication number
WO1999036082A3
WO1999036082A3 PCT/CA1999/000006 CA9900006W WO9936082A3 WO 1999036082 A3 WO1999036082 A3 WO 1999036082A3 CA 9900006 W CA9900006 W CA 9900006W WO 9936082 A3 WO9936082 A3 WO 9936082A3
Authority
WO
WIPO (PCT)
Prior art keywords
oxidative stress
protection
protein levels
therapy against
neurofilament protein
Prior art date
Application number
PCT/CA1999/000006
Other languages
French (fr)
Other versions
WO1999036082A2 (en
Inventor
Jean-Pierre Julien
Sebastien Couillard-Despres
Qinzhang Zhu
Original Assignee
Julien Jean Pierre
Couillard Despres Sebastien
Qinzhang Zhu
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Julien Jean Pierre, Couillard Despres Sebastien, Qinzhang Zhu filed Critical Julien Jean Pierre
Priority to AU19564/99A priority Critical patent/AU1956499A/en
Publication of WO1999036082A2 publication Critical patent/WO1999036082A2/en
Publication of WO1999036082A3 publication Critical patent/WO1999036082A3/en

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/1703—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates
    • A61K38/1709—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K48/00—Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Immunology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Chemical & Material Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Marine Sciences & Fisheries (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Zoology (AREA)
  • Epidemiology (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)

Abstract

The present invention describes the use of increased levels of NF proteins to provide protection against reactive oxygen species and neurodegeneration associated with oxidative stress. The neurodegeneration associated with oxidative stress may be due to aging, injury, or neurodegenerative disorders, such as Amyotrophic lateral sclerosis (ALS), Alzheimer's disease, Parkinson's disease, Giant Axonal Neuropathy, neuropathies associated with diabetes, toxic neuropathies, Lewy body Dementia, or Guam-Parkinsonism.
PCT/CA1999/000006 1998-01-13 1999-01-13 The use of increased neurofilament protein levels as protection and therapy against neurodegeneration with oxidative stress involvement WO1999036082A2 (en)

Priority Applications (1)

Application Number Priority Date Filing Date Title
AU19564/99A AU1956499A (en) 1998-01-13 1999-01-13 The use of increased neurofilament protein levels as protection and therapy against neurodegeneration with oxidative stress involvement

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
CA2226788 1998-01-13
CA2,226,788 1998-01-13

Publications (2)

Publication Number Publication Date
WO1999036082A2 WO1999036082A2 (en) 1999-07-22
WO1999036082A3 true WO1999036082A3 (en) 1999-09-23

Family

ID=4161984

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/CA1999/000006 WO1999036082A2 (en) 1998-01-13 1999-01-13 The use of increased neurofilament protein levels as protection and therapy against neurodegeneration with oxidative stress involvement

Country Status (2)

Country Link
AU (1) AU1956499A (en)
WO (1) WO1999036082A2 (en)

Families Citing this family (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP5116937B2 (en) 2003-09-16 2013-01-09 独立行政法人国立がん研究センター Method for evaluating the degree of canceration of a mammal-derived specimen
US10024870B2 (en) * 2014-04-02 2018-07-17 Wisconsin Alumni Research Foundation Therapeutic and diagnostic methods and compositions for neurodegenerative diseases

Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO1998003190A1 (en) * 1996-07-19 1998-01-29 Neurotrauma Therapeutics, Inc. Calpain inhibitors for the treatment of traumatic brain injury

Patent Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO1998003190A1 (en) * 1996-07-19 1998-01-29 Neurotrauma Therapeutics, Inc. Calpain inhibitors for the treatment of traumatic brain injury

Non-Patent Citations (2)

* Cited by examiner, † Cited by third party
Title
P.-H. TU ET AL.: "OXIDATIVE STRESS, MUTANT SOD1, AND NEUROFILAMENT PATHOLOGY IN TRANSGENIC MOUSE MODELS OF HUMAN MOTOR NEURON DISEASE", LABORATORY INVESTIGATION, vol. 76, no. 4, April 1997 (1997-04-01), BALTIMORE, PA, US, pages 441 - 456, XP002110691 *
S.M. CHOU ET AL.: "ROLE OF SOD-1 AND NITRIC OXIDE/CYCLIC GMP CASCADE ON NEUROFILAMENT AGGREGATION IN ALS/MND.", JOURNAL OF THE NEUROLOGICAL SCIENCES, vol. 139, no. SUPPL., 1996, AMSTERDAM, NL, pages 16 - 26, XP002110692 *

Also Published As

Publication number Publication date
WO1999036082A2 (en) 1999-07-22
AU1956499A (en) 1999-08-02

Similar Documents

Publication Publication Date Title
WO2003053997A3 (en) Methods of increasing endogenous erythropoietin (epo)
CA2316808A1 (en) Transgenic rabbit that expresses a functional human lipoprotein (a)
IL216579A0 (en) Aminocyclohexyl ether derivatives and pharmaceutical compositions containing the same
WO1999048482A3 (en) Smilagenin and anzurogenin-d for the treatment of alzheimer's disease
EP1765388B8 (en) Combination therapy for preventing or treating alzheimer's disease, and kit therefor
WO2004074232A8 (en) 1-phenylalkanecarboxylic acid derivatives for the treatment of neurodegenerative diseases
CA2172513A1 (en) Aminocyclohexylesters and uses thereof
AU2001257451A1 (en) Use of medium chain triglycerides for the treatment and prevention of alzheimer's disease and other diseases resulting from reduced neuronal metabolism
WO1992013878A3 (en) Conformationally restricted mimetics of beta turns and beta bulges and peptides containing the same
WO2006035237A3 (en) Methods and compositions relating to alzheimer's disease
IL104655A0 (en) Stabilized radiopharmaceutical kits
AU3967097A (en) Novel compounds and compositions for treating diseases associated with tryptase activity
WO2002051433A3 (en) Use of artemin, a member of the gdnf ligand family for preparing a neuroprotective medicament
WO2001058476A3 (en) Methods and compositions for treatment of alzheimer's disease by enhancing plasmin or plasmin-like activity
WO2000009553A3 (en) Antimicrobial peptides isolated from the skin of american frogs
ZA977310B (en) Transdermal propentofylline compositions for the treatment of Alzheimer's disease.
AU6232794A (en) The use of nitric oxide-delivering compounds for the treatment or prevention of alcoholic liver injury
AU2002315131A1 (en) Aminediols as agents for the treatment of alzheimer's disease
IL120443A0 (en) Heterocyclic compounds for the treatment of pancreatitis
WO1993015112A3 (en) COMPOUNDS AND METHODS FOR INHIBITING β-PROTEIN FUNCTION
WO1999036082A3 (en) The use of increased neurofilament protein levels as protection and therapy against neurodegeneration with oxidative stress involvement
AU2003238046A1 (en) Substituted 3- and 4- aminomethylpiperidines for use as beta-secretase in the treatment of alzheimer's disease
WO2000023587A3 (en) Gene therapy of alzheimer's disease by delivery of an encoded apolipoprotein e
AU2001254634A1 (en) Use of neuregulin-beta as an indicator and/or target
DE69816776D1 (en) Modified catalase, composition containing it and process for the preparation of the catalase

Legal Events

Date Code Title Description
AK Designated states

Kind code of ref document: A2

Designated state(s): AL AM AT AU AZ BA BB BG BR BY CA CH CN CU CZ DE DK EE ES FI GB GD GE GH GM HR HU ID IL IN IS JP KE KG KP KR KZ LC LK LR LS LT LU LV MD MG MK MN MW MX NO NZ PL PT RO RU SD SE SG SI SK SL TJ TM TR TT UA UG US UZ VN YU ZW

AL Designated countries for regional patents

Kind code of ref document: A2

Designated state(s): GH GM KE LS MW SD SZ UG ZW AM AZ BY KG KZ MD RU TJ TM AT BE CH CY DE DK ES FI FR GB GR IE IT LU MC NL PT SE BF BJ CF CG CI CM GA GN GW ML MR NE SN TD TG

121 Ep: the epo has been informed by wipo that ep was designated in this application
AK Designated states

Kind code of ref document: A3

Designated state(s): AL AM AT AU AZ BA BB BG BR BY CA CH CN CU CZ DE DK EE ES FI GB GD GE GH GM HR HU ID IL IN IS JP KE KG KP KR KZ LC LK LR LS LT LU LV MD MG MK MN MW MX NO NZ PL PT RO RU SD SE SG SI SK SL TJ TM TR TT UA UG US UZ VN YU ZW

AL Designated countries for regional patents

Kind code of ref document: A3

Designated state(s): GH GM KE LS MW SD SZ UG ZW AM AZ BY KG KZ MD RU TJ TM AT BE CH CY DE DK ES FI FR GB GR IE IT LU MC NL PT SE BF BJ CF CG CI CM GA GN GW ML MR NE SN TD TG

DFPE Request for preliminary examination filed prior to expiration of 19th month from priority date (pct application filed before 20040101)
NENP Non-entry into the national phase

Ref country code: KR

REG Reference to national code

Ref country code: DE

Ref legal event code: 8642

122 Ep: pct application non-entry in european phase
NENP Non-entry into the national phase

Ref country code: CA